Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM)

Hannah Carter, Josue Samayoa, Ralph H. Hruban, Rachel Karchin

Research output: Contribution to journalArticlepeer-review

Abstract

Over 20,000 genes were recently sequenced in a series of 24 pancreatic cancers. We applied CHASM (Cancer-specific High-throughput Annotation of Somatic Mutations) to 963 of the missense somatic missense mutations discovered in these 24 cancers. CHASM identified putative driver mutations (false discovery rate ≤0.3) in three known pancreatic cancer driver genes (P53, SMAD4, CDKN2A). An additional 15 genes with putative driver mutations include genes coding for kinases (PIK3CG, DGKA, STK33, TTK and PRKCG), for cell cycle related proteins (NEK8), and for proteins involved in cell adhesion (CMAS, PCDHB2). These and other mutations identified by CHASM point to potential "driver genes" in pancreatic cancer that should be prioritized for additional follow-up.

Original languageEnglish (US)
Pages (from-to)582-587
Number of pages6
JournalCancer Biology and Therapy
Volume10
Issue number6
DOIs
StatePublished - Sep 15 2010

Keywords

  • CHASM
  • Cancer drivers
  • Missense mutations
  • Pancreatic cancer
  • Somatic mutations

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM)'. Together they form a unique fingerprint.

Cite this